AI summary · may contain errors
Mezigdomide treatment of ex vivo generated exhausted T cells in multiple myeloma is linked to decreased exhaustion-marker expression and increased proinflammatory cytokine expression.
- 1 cited this week
- Open access
Elsevier BV · Clinical Medicine · ISSN 0006-4971, 1528-0020
Rebuilt
AI summary · may contain errors
Mezigdomide treatment of ex vivo generated exhausted T cells in multiple myeloma is linked to decreased exhaustion-marker expression and increased proinflammatory cytokine expression.
AI summary · may contain errors
In newly diagnosed light-chain (AL) amyloidosis, adding subcutaneous daratumumab to VCd (D-VCd) improved overall survival with a hazard ratio of 0.62 after 61.4 months’ follow-up.
Newest first · last 60 days
AI summary · may contain errors
Cytokine-enhanced CAR T-cell designs—starting with IL-12 and expanding through common g-chain cytokines and IL-18—aim to improve expansion, persistence, and function while managing toxicity risks.
AI summary · may contain errors
Pre-clinical murine studies show CNS graft-versus-host disease involves disrupted vascular/lymphatic barriers and neuroinflammatory signaling, with IL-6 and TNF-α linked to compartment-specific pathology.
AI summary · may contain errors
Etentamig achieved objective responses in 66% of 146 adult patients with relapsed/refractory multiple myeloma, with ≥very good partial responses in 54%.
AI summary · may contain errors
Systemic butyrate or propionate administration in mouse cGVHD models mitigates disease and improves survival by reducing pathogenic hyperexpanded B cells and recipient-specific IgA.
AI summary · may contain errors
In transplant-eligible newly diagnosed multiple myeloma patients ≤65, KRd-ASCT with carfilzomib-lenalidomide-dexamethasone achieved longer progression-free survival (median 98 months) than KRd12 (70) and KCd-ASCT (67).
AI summary · may contain errors
In humanized sickle cell disease mice, regenerative stress is linked to higher clonal hematopoiesis burden and MDS-like dysplastic features, with HSPC mutational profiles resembling aged mice.
AI summary · may contain errors
Baseline and response reporting in myelodysplastic syndromes/neoplasms trials shows substantial variability, with baseline ANC reported in 16% of lower-risk and 23% of higher-risk studies.
AI summary · may contain errors
High-risk CCUS patients (n=409) defined by CHRS or CCRS show clinical features and event rates comparable to lower-risk MDS (n=241), despite morphology-based uncertainty.
AI summary · may contain errors
In a prospective cohort of 242 patients with provoked deep vein thrombosis and/or pulmonary embolism, 24-month recurrence risk was 19.7% after major transient risk factors.
AI summary · may contain errors
In the phase 1/2 TRANSCEND CLL 004 study, liso-cel plus ibrutinib in R/R CLL/SLL achieved a 45% CR/CRi rate at DL2.
AI summary · may contain errors
hAB2 CAR-T cells selectively eradicate CALRmut myeloproliferative neoplasm–sustaining stem cells in patient-derived tumor xenografts, eliminating all detectable MPN-propagating function in serial transplantation assays.
AI summary · may contain errors
Large NET networks formed by NLRP3 inflammasome activation, peptidylarginine deiminase 4, and neutrophil enzymes are central to disease pathogenesis across many chronic disorders.
AI summary · may contain errors
Sapablursen reduced phlebotomy frequency in phlebotomy-dependent polycythemia vera, cutting weekly rates by -0.10 in both cohort A (n=32) and cohort B (n=17).
AI summary · may contain errors
Adenine base editing corrected the recurrent STAT1 p.T385M gain-of-function mutation with >90% efficiency in patient T cells and HSCs, restoring STAT1 signaling and immune function.
AI summary · may contain errors
CD70 overexpression at diagnosis in uniformly treated follicular lymphoma is linked to inferior progression-free survival, with CD70⁺ tumor cells showing enhanced proliferation and immune activation.
AI summary · may contain errors
In CIBMTR registry patients aged ≥50 with AML/MDS receiving allogeneic HCT, fludarabine–melphalan regimens (FM100, FM140) showed superior late overall survival versus fludarabine–busulfan (FB2), with HR 0.79 and 0.77.
AI summary · may contain errors
In Th3 mouse models of non-transfusion-dependent β-thalassemia, Tmprss6 antisense oligonucleotides increased phospho-Smad1/5/8 and hepcidin and improved iron outcomes, but failed in ERFE-overexpressing Th3 mice.
AI summary · may contain errors
Pivekimab sunirine, an anti-CD123 antibody-drug conjugate, was approved by the FDA on May 27, 2026, for adults with blastic plasmacytoid dendritic cell neoplasm based on CADENZA.
AI summary · may contain errors
Circulating tumor DNA can detect measurable residual disease after frontline therapy in large B-cell lymphoma, addressing molecular-only relapse that PET misses.
AI summary · may contain errors
Nur77 loss in hematopoietic stem and progenitor cells is linked to diabetic anemia, and restoring Nur77 with cytosporone B prevents anemia in diabetic mice.
AI summary · may contain errors
An international consensus guideline for measurable residual disease (MRD) assessment in acute lymphoblastic leukemia (ALL) reached agreement on 38 of 41 statements, standardizing methods and definitions.
AI summary · may contain errors
High-sensitivity detection and quantitative monitoring of amyloidogenic immunoglobulin light chains are critical for early diagnosis and relapse detection in AL amyloidosis, enabling better organ preservation.
Journals this month
Topics moving, week to 18 Nov 2026
By field